BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has been given a consensus rating of “Moderate Buy” by the fifteen analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $140.0314.

A number of equities analysts have weighed in on BNTX shares. UBS Group upgraded BioNTech to a “hold” rating in a research note on Thursday, December 4th. JPMorgan Chase & Co. reduced their price target on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. Jefferies Financial Group reissued a “buy” rating and issued a $151.00 price target on shares of BioNTech in a report on Wednesday, December 3rd. HC Wainwright reaffirmed a “buy” rating and set a $140.00 price objective on shares of BioNTech in a research note on Thursday, December 11th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a report on Friday.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently modified their holdings of BNTX. Dodge & Cox grew its position in shares of BioNTech by 315.7% during the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares during the period. BNP Paribas Financial Markets boosted its position in BioNTech by 6.7% during the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock worth $135,800,000 after purchasing an additional 80,005 shares in the last quarter. Bank of New York Mellon Corp boosted its position in BioNTech by 58.8% during the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock worth $118,045,000 after purchasing an additional 410,351 shares in the last quarter. Franklin Resources Inc. grew its holdings in BioNTech by 76.8% in the second quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after purchasing an additional 326,556 shares during the period. Finally, Aberdeen Group plc increased its position in shares of BioNTech by 87.2% in the second quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock valued at $76,864,000 after buying an additional 336,260 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Down 2.1%

BNTX stock opened at $115.98 on Monday. The company has a market capitalization of $26.12 billion, a P/E ratio of -44.10 and a beta of 1.40. BioNTech has a 12 month low of $81.20 and a 12 month high of $126.77. The firm’s fifty day simple moving average is $99.39 and its 200-day simple moving average is $103.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The business had revenue of $1.78 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same period last year, the business earned $0.81 EPS. The company’s revenue for the quarter was up 22.0% on a year-over-year basis. As a group, equities research analysts forecast that BioNTech will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.